{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:04:48Z","timestamp":1772762688048,"version":"3.50.1"},"reference-count":104,"publisher":"JLE","issue":"6","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.nephro.2014.04.001","type":"journal-article","created":{"date-parts":[[2014,7,26]],"date-time":"2014-07-26T14:15:20Z","timestamp":1406384120000},"page":"441-450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effets pl\u00e9\u00efotropes du s\u00e9v\u00e9lamer, pr\u00e9curseur d\u2019agent ch\u00e9lateur de la voie intestinale"],"prefix":"10.1684","volume":"10","author":[{"given":"Ziad A.","family":"Massy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Maizel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","reference":[{"issue":"1\u00a0Suppl.\u00a01","key":"10.1016\/j.nephro.2014.04.001_bib0005","first-page":"S1","article-title":"Excerpts from the United States Renal Data System 2004\u00a0annual data report: atlas of end-stage renal disease in the United States","volume":"45","author":"USRDS","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2014.04.001_bib0525","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S1769-7255(10)70010-9","article-title":"Rapport Rein 2008 - Synth\u00e8se","volume":"6","author":"R\u00e9seau \u00e9pid\u00e9miologie et information en n\u00e9phrologie","year":"2010","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.nephro.2014.04.001_bib0015","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1053\/ajkd.1998.v32.pm9820470","article-title":"Clinical epidemiology of cardiovascular disease in chronic renal disease","volume":"32","author":"Foley","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2014.04.001_bib0020","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nrneph.2010.143","article-title":"Atherosclerosis in CKD: differences from the general population","volume":"6","author":"Dr\u00fceke","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.nephro.2014.04.001_bib0025","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0272-6386(96)90363-7","article-title":"Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients","volume":"27","author":"Braun","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2014.04.001_bib0030","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM200005183422003","article-title":"Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis","volume":"342","author":"Goodman","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2014.04.001_bib0035","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/ndt\/12.4.718","article-title":"Onset of coronary artery disease prior to initiation of haemodialysis in patients with end-stage renal disease","volume":"12","author":"Joki","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2014.04.001_bib0040","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1681\/ASN.2004090765","article-title":"High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination","volume":"16","author":"Ohtake","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.04.001_bib0045","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/ndt\/gfg414","article-title":"Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality","volume":"18","author":"London","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2014.04.001_bib0050","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/00365590410031715","article-title":"Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease","volume":"38","author":"Yao","year":"2004","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.nephro.2014.04.001_bib0055","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1161\/01.RES.87.7.e10","article-title":"Phosphate regulation of vascular smooth muscle cell calcification","volume":"87","author":"Jono","year":"2000","journal-title":"Circ Res"},{"key":"10.1016\/j.nephro.2014.04.001_bib0060","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1161\/hh2401.101070","article-title":"Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1\u00a0and downregulation of smooth muscle lineage markers","volume":"89","author":"Steitz","year":"2001","journal-title":"Circ Res"},{"key":"10.1016\/j.nephro.2014.04.001_bib0065","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0272-6386(99)70221-0","article-title":"A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients","volume":"33","author":"Bleyer","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2014.04.001_bib0070","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/j.1523-1755.2005.00600.x","article-title":"Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis","volume":"68","author":"Block","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2014.04.001_bib0075","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","article-title":"Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients","volume":"62","author":"Chertow","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2014.04.001_bib0080","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1053\/j.ajkd.2005.12.039","article-title":"A randomized crossover trial comparing sevelamer with calcium acetate in children with CKD","volume":"47","author":"Pieper","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2014.04.001_bib0085","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1744-9987.2007.00432.x","article-title":"Sevelamer hydrochloride exacerbates metabolic acidosis in hemodialysis patients, depending on the dosage","volume":"11","author":"Oka","year":"2007","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.nephro.2014.04.001_bib0090","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/ndt\/gfq598","article-title":"The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol","volume":"26","author":"Pierce","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2014.04.001_bib0095","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1681\/ASN.2005121320","article-title":"Lipids and renal disease","volume":"17","author":"Trevisan","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.04.001_bib0100","doi-asserted-by":"crossref","first-page":"F262","DOI":"10.1152\/ajprenal.00099.2005","article-title":"Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences","volume":"290","author":"Vaziri","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.nephro.2014.04.001_bib0105","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/ki.2013.181","article-title":"LDL cholesterol in CKD\u2013to treat or not to treat?","volume":"84","author":"Massy","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2014.04.001_bib0110","first-page":"381","article-title":"Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients","volume":"50","author":"Wilkes","year":"1998","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nephro.2014.04.001_bib0115","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1046\/j.1523-1755.2002.00459.x","article-title":"Bile acid binding to sevelamer HCl","volume":"62","author":"Braunlin","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2014.04.001_bib0120","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1097\/01.ASN.0000088024.72216.2E","article-title":"Chronic renal failure accelerates atherogenesis in apolipoprotein E-deficient mice","volume":"14","author":"Bro","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.04.001_bib0125","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/01.ASN.0000045048.71975.FC","article-title":"The apolipoprotein E knockout mouse: a model documenting accelerated atherogenesis in uremia","volume":"14","author":"Buzello","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.04.001_bib0130","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1681\/ASN.2004060495","article-title":"Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice","volume":"16","author":"Massy","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.04.001_bib0135","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1161\/CIRCULATIONAHA105.541854","article-title":"Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice","volume":"112","author":"Phan","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.nephro.2014.04.001_bib0140","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1681\/ASN.2006050490","article-title":"Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy","volume":"18","author":"Mathew","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.04.001_bib0145","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ahj.2004.07.023","article-title":"Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients","volume":"149","author":"Ferramosca","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.nephro.2014.04.001_bib0150","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1093\/ndt\/14.12.2907","article-title":"Long-term effects of sevelamer hydrochloride on the calcium\u00d7phosphate product and lipid profile of haemodialysis patients","volume":"14","author":"Chertow","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2014.04.001_bib0155","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1081\/JDI-65259","article-title":"Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients","volume":"27","author":"Yamada","year":"2005","journal-title":"Ren Fail"},{"key":"10.1016\/j.nephro.2014.04.001_bib0160","doi-asserted-by":"crossref","first-page":"c83","DOI":"10.1159\/000319654","article-title":"Effect of sevelamer hydrochloride exposure on carotid intima media thickness in hemodialysis patients","volume":"117","author":"Boaz","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.nephro.2014.04.001_bib0165","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/ndt\/16.3.459","article-title":"Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment","volume":"16","author":"Locatelli","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2014.04.001_bib0170","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2013an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2014.04.001_bib0175","doi-asserted-by":"crossref","first-page":"20A","DOI":"10.1016\/j.amjcard.2005.11.012","article-title":"Inflammation in renal disease","volume":"97","author":"Vidt","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.nephro.2014.04.001_bib0180","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1523-1755.61.s80.18.x","article-title":"Inflammation and cardiovascular risk in dialysis patients","volume":"80","author":"Wanner","year":"2002","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.nephro.2014.04.001_bib0185","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1046\/j.1523-1755.1999.00273.x","article-title":"Inflammation enhances cardiovascular risk and mortality in hemodialysis patients","volume":"55","author":"Zimmermann","year":"1999","journal-title":"Kidney Int"},{"issue":"Suppl. 8","key":"10.1016\/j.nephro.2014.04.001_bib0190","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/ndt\/17.suppl_8.29","article-title":"C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients","volume":"17","author":"Wanner","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2014.04.001_bib0195","first-page":"879","article-title":"Prognostic value of C-reactive protein for heart disease in dialysis patients","volume":"6","author":"Wang","year":"2005","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.nephro.2014.04.001_bib0200","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1161\/01.RES.0000171451.88616.c2","article-title":"Proinflammatory activation of macrophages by basic calcium phosphate crystals via protein kinase C and MAP kinase pathways: a vicious cycle of inflammation and arterial calcification?","volume":"96","author":"Nadra","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.nephro.2014.04.001_bib0205","doi-asserted-by":"crossref","first-page":"934","DOI":"10.2215\/CJN.12891211","article-title":"Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease","volume":"7","author":"Vlassara","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.04.001_bib0210","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/ndt\/16.2.335","article-title":"Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment","volume":"16","author":"Nguyen-Khoa","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2014.04.001_bib0215","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000319850","article-title":"Sevelamer carbonate reduces inflammation and endotoxemia in an animal model of uremia","volume":"30","author":"Hauser","year":"2010","journal-title":"Blood Purif"},{"key":"10.1016\/j.nephro.2014.04.001_bib0220","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2215\/CJN.01650211","article-title":"Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients","volume":"6","author":"Navarro-Gonz\u00e1lez","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.04.001_bib0225","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000089434","article-title":"What is uremia? Retention versus oxidation","volume":"24","author":"Vanholder","year":"2006","journal-title":"Blood Purif"},{"key":"10.1016\/j.nephro.2014.04.001_bib0230","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/ndt\/18.3.463","article-title":"Uraemic toxins and cardiovascular disease","volume":"18","author":"Vanholder","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2014.04.001_bib0235","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1046\/j.1523-1755.2003.00924.x","article-title":"Review on uremic toxins: classification, concentration, and interindividual variability","volume":"63","author":"Vanholder","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2014.04.001_bib0240","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/ndt\/15.1.50","article-title":"Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane","volume":"15","author":"Lesaffer","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2014.04.001_bib0245","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1523-1755.2004.00399.x","article-title":"The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair","volume":"65","author":"Dou","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2014.04.001_bib0250","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/sj.ki.5000115","article-title":"Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients","volume":"69","author":"Bammens","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2014.04.001_bib0255","first-page":"505A","article-title":"Sevelamer hydrochloride (Renagel) absorbs the uremic compounds indoxyl sulfate, indole and p cresol","volume":"15","author":"De Smet","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.04.001_bib0260","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1744-9987.2010.00891.x","article-title":"Uremic toxins and oral adsorbents","volume":"15","author":"Goto","year":"2011","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.nephro.2014.04.001_bib0265","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1253\/circj.CJ-10-0355","article-title":"Association between fibroblast growth factor 23\u00a0and left ventricular hypertrophy in maintenance hemodialysis patients. Comparison with B-type natriuretic peptide and cardiac troponin T","volume":"74","author":"Negishi","year":"2010","journal-title":"Circ J"},{"key":"10.1016\/j.nephro.2014.04.001_bib0270","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.2215\/CJN.02560310","article-title":"Fibroblast growth factor 23\u00a0and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease","volume":"5","author":"Kanbay","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.04.001_bib0275","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23\u00a0and mortality among patients undergoing hemodialysis","volume":"359","author":"Guti\u00e9rrez","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2014.04.001_bib0280","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23\u00a0induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nephro.2014.04.001_bib0285","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2215\/CJN.05420709","article-title":"Early control of PTH and FGF23\u00a0in normophosphatemic CKD patients: a new target in CKD-MBD therapy?","volume":"5","author":"Oliveira","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.04.001_bib0290","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1053\/j.ajkd.2011.11.007","article-title":"Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23\u00a0in CKD patients: a randomized clinical trial","volume":"59","author":"Yilmaz","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2014.04.001_bib0295","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1681\/ASN.2012030223","article-title":"Effects of phosphate binders in moderate CKD","volume":"23","author":"Block","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.04.001_bib0300","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1681\/ASN.2012060569","article-title":"Phosphate binders in CKD: bad news or good news?","volume":"23","author":"Dr\u00fceke","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.04.001_bib0305","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ki.2013.110","article-title":"Effects of sevelamer treatment on cardiovascular abnormalities in mice with chronic renal failure","volume":"84","author":"Maizel","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2014.04.001_bib0310","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1093\/ndt\/gfq053","article-title":"Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study","volume":"25","author":"Brandenburg","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2014.04.001_bib0315","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1681\/ASN.2012070719","article-title":"Cardiovascular effects of sevelamer in stage 3\u00a0CKD","volume":"24","author":"Chue","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.04.001_bib0320","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/art.20781","article-title":"Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial","volume":"52","author":"Garg","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nephro.2014.04.001_bib0325","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1097\/00004872-200018080-00021","article-title":"Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP)","volume":"18","author":"Franse","year":"2000","journal-title":"J Hypertens"},{"key":"10.1016\/j.nephro.2014.04.001_bib0330","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1161\/hs0402.105927","article-title":"Prognostic significance of uric acid serum concentration in patients with acute ischemic stroke","volume":"33","author":"Chamorro","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.nephro.2014.04.001_bib0335","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/sj.ki.5000391","article-title":"Unearthing uric acid: an ancient factor with recently found significance in renal and cardiovascular disease","volume":"69","author":"Nakagawa","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2014.04.001_bib0340","first-page":"448","article-title":"RenaGel efficacy in severe secondary hyperparathyroidism","volume":"22","author":"Castro","year":"2002","journal-title":"Nefrologia"},{"key":"10.1016\/j.nephro.2014.04.001_bib0345","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/ndt\/gfn488","article-title":"Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis","volume":"24","author":"Evenepoel","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2014.04.001_bib0350","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/ndt\/gfr254","article-title":"Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice","volume":"27","author":"Nikolov","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2014.04.001_bib0355","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/11539120-000000000-00000","article-title":"Pleiotropic effects of sevelamer beyond phosphate binding in end-stage renal disease patients: a randomized, open-label, parallel-group study","volume":"31","author":"Lin","year":"2011","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.nephro.2014.04.001_bib0360","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1542-4758.2009.00369.x","article-title":"Effect of phosphate binders on oxidative stress and inflammation markers in hemodialysis patients","volume":"13","author":"Peres","year":"2009","journal-title":"Hemodial Int"},{"key":"10.1016\/j.nephro.2014.04.001_bib0365","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1111\/j.1523-1755.2005.00345.x","article-title":"Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin","volume":"67","author":"Stenvinkel","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2014.04.001_bib0370","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1365-2362.2008.02032.x","article-title":"Low serum fetuin-A concentration predicts poor outcome only in the presence of inflammation in prevalent haemodialysis patients","volume":"38","author":"Metry","year":"2008","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.nephro.2014.04.001_bib0375","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/hr.2012.136","article-title":"Subclinical atherosclerosis and fetuin-A plasma levels in essential hypertensive patients","volume":"36","author":"Guarneri","year":"2013","journal-title":"Hypertens Res"},{"key":"10.1016\/j.nephro.2014.04.001_bib0380","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.jacc.2011.08.035","article-title":"The associations of fetuin-A with subclinical cardiovascular disease in community-dwelling persons: the Rancho Bernardo Study","volume":"58","author":"Ix","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nephro.2014.04.001_bib0385","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2215\/CJN.02810707","article-title":"Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4\u00a0patients","volume":"3","author":"Caglar","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.04.001_bib0390","doi-asserted-by":"crossref","first-page":"968","DOI":"10.2337\/dc10-1675","article-title":"Protection from retinopathy and other complications in patients with type 1\u00a0diabetes of extreme duration: the joslin 50-year medalist study","volume":"34","author":"Sun","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.nephro.2014.04.001_bib0395","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1159\/000108104","article-title":"Effects of pyridoxamine in combined phase 2\u00a0studies of patients with type 1\u00a0and type 2\u00a0diabetes and overt nephropathy","volume":"27","author":"Williams","year":"2007","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nephro.2014.04.001_bib0400","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1681\/ASN.2011030272","article-title":"Pyridorin in type 2\u00a0diabetic nephropathy","volume":"23","author":"Lewis","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.04.001_bib0405","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.2337\/dc11-0091","article-title":"Restriction of advanced glycation end products improves insulin resistance in human type 2\u00a0diabetes: potential role of AGER1\u00a0and SIRT1","volume":"34","author":"Uribarri","year":"2011","journal-title":"Diabetes Care"},{"issue":"Suppl.\u00a02","key":"10.1016\/j.nephro.2014.04.001_bib0410","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2337\/diab.41.2.S36","article-title":"Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia","volume":"41","author":"Monnier","year":"1992","journal-title":"Diabetes"},{"key":"10.1016\/j.nephro.2014.04.001_bib0415","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1053\/j.ajkd.2010.10.055","article-title":"Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients","volume":"57","author":"Kakuta","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2014.04.001_bib0420","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.atherosclerosis.2011.02.017","article-title":"Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease\u2013a cross-sectional study of predialysis, dialysis and kidney-transplantation patients","volume":"216","author":"Recio-Mayoral","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.nephro.2014.04.001_bib0425","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1046\/j.1523-1755.1998.00947.x","article-title":"Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension","volume":"53","author":"Vaziri","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2014.04.001_bib0430","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/CIRCULATIONAHA.108.797407","article-title":"Mechanisms of aortic and cardiac dysfunction in uremic mice with aortic calcification","volume":"119","author":"Maizel","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.nephro.2014.04.001_bib0435","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/cvr\/cvs240","article-title":"Effects of phosphate on vascular function under normal conditions and influence of the uraemic state","volume":"96","author":"Six","year":"2012","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.nephro.2014.04.001_bib0440","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1681\/ASN.2008101106","article-title":"Dietary phosphorus acutely impairs endothelial function","volume":"20","author":"Shuto","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.04.001_bib0445","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1111\/j.1523-1755.2004.00894.x","article-title":"The burden of kidney disease: improving global outcomes","volume":"66","author":"Eknoyan","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2014.04.001_bib0450","series-title":"Clinical guide to the Basics of bone and mineral metabolism in CKD","first-page":"96","article-title":"Morbidity and mortality associated with abnormalities in bone and mineral metabolism in CKD","author":"Block","year":"2006"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.nephro.2014.04.001_bib0455","doi-asserted-by":"crossref","first-page":"i9","DOI":"10.1093\/ndt\/gfh1002","article-title":"The importance of bone health in end-stage renal disease: out of the frying pan, into the fire?","volume":"19","author":"Malluche","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2014.04.001_bib0460","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2014.04.001_bib0465","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1359\/JBMR.041221","article-title":"Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis","volume":"20","author":"Raggi","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.nephro.2014.04.001_bib0470","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1681\/ASN.2006101089","article-title":"Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients","volume":"19","author":"Ferreira","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2014.04.001_bib0475","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/sj.ki.5002164","article-title":"Association of pulse wave velocity with vascular and valvular calcification in hemodialysis patients","volume":"71","author":"Raggi","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2014.04.001_bib0480","doi-asserted-by":"crossref","first-page":"c273","DOI":"10.1159\/000170783","article-title":"Phosphate binder impact on bone remodeling and coronary calcification\u2013results from the BRiC study","volume":"110","author":"Barreto","year":"2008","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.nephro.2014.04.001_bib0485","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1053\/j.ajkd.2008.02.298","article-title":"A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study","volume":"51","author":"Qunibi","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2014.04.001_bib0490","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s10157-012-0640-4","article-title":"Effects of sevelamer hydrochloride on mortality, lipid abnormality and arterial stiffness in hemodialyzed patients: a propensity-matched observational study","volume":"16","author":"Iimori","year":"2012","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.nephro.2014.04.001_bib0495","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/sj.ki.5002059","article-title":"Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients","volume":"71","author":"Block","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2014.04.001_bib0500","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1365-2710.2007.00871.x","article-title":"Survival in end stage renal disease: calcium carbonate vs. sevelamer","volume":"32","author":"Borzecki","year":"2007","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.nephro.2014.04.001_bib0505","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","article-title":"Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients","volume":"72","author":"Suki","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2014.04.001_bib0510","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1053\/j.ajkd.2007.12.002","article-title":"A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data","volume":"51","author":"Saint Peter","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2014.04.001_bib0515","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1053\/j.ajkd.2013.03.023","article-title":"Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial","volume":"62","author":"Di Iorio","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2014.04.001_bib0520","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(13)60897-1","article-title":"Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis","volume":"382","author":"Jamal","year":"2013","journal-title":"Lancet"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725514000972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725514000972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2014.04.001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T15:01:47Z","timestamp":1741186907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725514000972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":104,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S1769725514000972"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2014.04.001","relation":{},"ISSN":["1769-7255"],"issn-type":[{"value":"1769-7255","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effets pl\u00e9\u00efotropes du s\u00e9v\u00e9lamer, pr\u00e9curseur d\u2019agent ch\u00e9lateur de la voie intestinale","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2014.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Association Soci\u00e9t\u00e9 de n\u00e9phrologie. Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}